Aktienanalyse zu Neogenomics Inc (NEO)NEONeogenomics Inc

NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing, interpretation and consultative services, molecular and NGS testing, comprehensive technical and professional services offering, clinical trials and research, validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics, Fluorescence In-Situ Hybridization (FISH), Flow cytometry, Molecular testing and others. It operates in the Healthcare sector (SERVICES-TESTING LABORATORIES industry).

NeoGenomics Inc is a good buy right now due to its recent positive developments, including a current price of $18.05 and a significant year-to-date change of +53.49%. The company has also recently expanded Medicare coverage for its RaDaR ST test, which is expected to enhance revenue streams. Additionally, the RSI is at 66.715, suggesting strong momentum, while the gross margin has improved to 45.56%. The main risk is the forward P/E ratio of 222.22, indicating high valuation expectations that may not be met.

9 analysts cover NEO: 8 rate it Buy, 1 Hold and 0 Sell. The average price target is 14.00.